Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
Provided By PR Newswire
Last update: Aug 13, 2025
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones
Read more at prnewswire.comNASDAQ:LUCD (11/6/2025, 3:45:39 PM)
1.085
-0.01 (-0.46%)
NASDAQ:PAVM (11/6/2025, 3:44:26 PM)
0.3226
-0.03 (-8.43%)
Find more stocks in the Stock Screener
